Baiyunshan
Baiyunshan is a brand.
Last updated October 9, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Baiyunshan is a Chinese pharmaceutical corporate brand associated with Guangzhou Pharmaceutical Group. The name is used in connection with Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd., a pharmaceutical enterprise established through the reorganization of businesses that had previously belonged to Guangzhou Pharmaceutical Group. According to the company’s official description, the reorganization was approved by China’s National Economic System Reform Commission in 1997. Guangzhou Pharmaceutical Group acted as the sole sponsor, contributing state-owned assets connected with the production and operating businesses of eight traditional Chinese medicine manufacturing enterprises and three pharmaceutical trading enterprises. The reorganization created a shareholding company with a broad pharmaceutical and healthcare scope. The business associated with Baiyunshan covers more than the manufacture of individual over-the-counter medicines. Its stated activities include asset operation, investment, development, financing, research and production of traditional Chinese medicines, production of biological products, health medicines and health beverages, and wholesale, retail and import-export operations involving traditional Chinese medicines, Western medicines and medical devices. This gives the brand a diversified position spanning pharmaceutical manufacturing, healthcare products and commercial distribution. Baiyunshan’s positioning is therefore best understood as a Chinese pharmaceutical and healthcare platform rather than as a narrowly defined single-product consumer brand. Its traditional Chinese medicine heritage is combined with chemical-pharmaceutical and broader healthcare capabilities. The company’s business structure also links manufacturing with wholesale, retail and international trade, allowing the brand to participate in several stages of the healthcare supply chain. The available reference material does not establish a separate founding date for a standalone Baiyunshan consumer brand, nor does it provide a verified list of current product families, executives, financial figures, stock information or international subsidiaries. Those details should be added only after confirmation from authoritative corporate filings, regulatory records or official product materials. On the available evidence, Baiyunshan is an active China-focused pharmaceutical corporate brand operating under the Guangzhou Pharmaceutical Group umbrella.
History
Baiyunshan is associated with Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd., which was formed in the late 1990s through a restructuring led by Guangzhou Pharmaceutical Group. The official company description states that the National Economic System Reform Commission approved the restructuring under approval document Ti Gai Sheng 1997 No. 139. Guangzhou Pharmaceutical Group served as the sole sponsor and contributed state-owned equity connected with eight traditional Chinese medicine manufacturing enterprises and three pharmaceutical trading enterprises. The resulting entity was established as a shareholding company in 1997. This formation reflected a broader restructuring approach in which existing pharmaceutical manufacturing and commercial assets were consolidated into a corporate platform capable of operating across production, investment and distribution. Rather than being limited to one traditional medicine factory or one consumer product, the Baiyunshan-associated business was designed to manage a portfolio of pharmaceutical and healthcare activities. The company’s official business scope includes asset management, investment, development and financing, alongside the development and manufacture of traditional Chinese medicines. It also identifies biological products, health medicines and health beverages among its production activities. On the commercial side, the business covers wholesale and retail of traditional Chinese medicines, Western medicines and medical devices, as well as import and export. This combination of manufacturing and distribution provides the historical basis for Baiyunshan’s broad pharmaceutical-platform positioning. The available reference material does not provide a sufficiently documented chronology of later acquisitions, product launches, leadership changes, campaigns, regulatory events or financial performance. It also does not establish whether every product sold by companies within the Guangzhou Pharmaceutical Group is marketed under the Baiyunshan name. Consequently, the history should distinguish the Baiyunshan-associated corporate entity from the wider Guangzhou Pharmaceutical Group and from individual product brands. Further development of this entry requires authoritative company filings, official annual reports, regulatory databases and verified product pages.
- 1997
Corporate restructuring approved
[1]China’s National Economic System Reform Commission approved the restructuring that led to the establishment of the Baiyunshan-associated shareholding company. Guangzhou Pharmaceutical Group was the sole sponsor and contributed state-owned operating assets from eight traditional Chinese medicine manufacturers and three pharmaceutical trading enterprises.
- 1997
Shareholding company established
[1]The reorganized enterprise was established as a shareholding company with activities spanning pharmaceutical manufacturing, healthcare products, investment and pharmaceutical commerce.
Products and positioning
A China-focused pharmaceutical and healthcare platform combining traditional Chinese medicine manufacturing with chemical medicines, biological and health products, and pharmaceutical distribution.
Pharmaceuticals
Traditional Chinese medicines
Traditional Chinese medicines are a core part of the business scope described by the company. The stated activities include their development and manufacture, reflecting the heritage of the manufacturing enterprises incorporated into the 1997 restructuring. No specific current product list is asserted here because the supplied reference does not identify individual Baiyunshan products.
Pharmaceuticals
Chemical medicines
The company’s commercial scope includes wholesale and retail of Western medicines, placing chemical medicines within the broader Baiyunshan-associated pharmaceutical portfolio. The available source does not establish specific formulations, therapeutic areas or product launch dates under the Baiyunshan name.
Healthcare products
Biological and health products
The official business description includes biological products, health medicines and health beverages. These activities extend the platform beyond conventional traditional Chinese medicine and connect it with broader consumer-health and preventive-health markets. Specific products and current brand architecture are not identified in the available material.
Pharmaceutical commerce
Pharmaceutical and medical-device distribution
Baiyunshan-associated operations include wholesale, retail and import-export activities for traditional Chinese medicines, Western medicines and medical devices. This distribution capability is an important part of the platform’s business model, complementing its manufacturing and healthcare-product activities.
Controversies
2025
Former GPHL and Baiyunshan chairman Li Chuyuan expelled from Party and public office
In May 2025, the Guangdong Provincial Commission for Discipline Inspection and Supervision announced that Li Chuyuan, former chairman of GPHL and Baiyunshan, was expelled from the Communist Party of China and dismissed from public office. Suspected crimes including illegal operation of similar business and bribery were transferred to procuratorial organs for examination and prosecution. The cited sources did not disclose a court judgment.
Sources5 sources
Cite this profile: Cite the canonical profile. /brand-wiki/baiyunshan · Editorial policy · How profiles are compiled